title: [Epidemiology and Pathophysiology of the acute respiratory distress syndrome (ARDS)].
abstract: Despite the implementation of a multimodal concept of treatment, the acute respiratory distress syndrome (ARDS) is still afflicted with high mortality rates. A reasonable application and combination of possible treatment strategies, such as prone position, positive end-expiratory pressure (PEEP), restrictive volume therapy or nitric oxide (NO), requires pathophysiological and epidemiological knowledge. In the following article we describe basic pathophysiological parameters in development, progression and therapy of ARDS. Furthermore, we try to elucidate possible reasons for considerable limitations of multicentric studies in this field.
authors.affiliation: Klinik für Anästhesiologie mit Schwerpunkt operative Intensivmedizin, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin. maria.deja@charite.de
authors.forename: Maria
authors.initials: M
authors.lastname: Deja
authors.forename: Christian
authors.initials: C
authors.lastname: Lojewski
authors.forename: Matthias
authors.initials: M
authors.lastname: Hommel
authors.forename: Mario
authors.initials: M
authors.lastname: Menk
authors.forename: Jörg
authors.initials: J
authors.lastname: Weimann
mesh_terms: D018450:Disease Progression; D005858:Germany / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D009569:Nitric Oxide / Q000627:therapeutic use; D010349:Patient Compliance; D011175:Positive-Pressure Respiration; D012128:Respiratory Distress Syndrome / Q000453:epidemiology* / Q000401:mortality / Q000503:physiopathology* / Q000628:therapy; D012138:Respiratory Therapy; D015996:Survival Rate; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D014665:Vasodilator Agents; D009569:Nitric Oxide